Taysha Gene Therapies, Inc. (TSHA) Dividend History

Company News

• Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

  Taysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.

  GlobeNewswire Inc.
• Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

  Taysha Gene Therapies, a clinical-stage biotechnology company, announced the pricing of a public offering of its common stock and pre-funded warrants, expected to raise approximately $200 million.

  GlobeNewswire Inc.
• Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a new employee an option to purchase 45,000 shares of the company's common stock as an inducement for their employment.

  GlobeNewswire Inc.
• Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement to join the company. The options have a 10-year term and will vest over four years.

  GlobeNewswire Inc.
• Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement for their employment. The options have a 10-year term and will vest over four years.

  GlobeNewswire Inc.